Notably, this study demonstrated that impaired ACE2 pathway might be a key player in SARS-CoV-2 related metabolic disorders, and identified imatinib, methazolamide and harpagoside as direct enzymatic activators of ACE2 by a high-throughput compound screening [52]. Here, ACE2 is linked to Other metabolic disease.